Back
Karyopharm Therapeutics 10K Form
Sell
28
KPTI
Karyopharm Therapeutics
Last Price:
0.85
Seasonality Move:
-2.8%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-08 | 10Q | KPTI/Karyopharm Therapeutics Quarterly |
| 2023-11-02 | 10Q | KPTI/Karyopharm Therapeutics Quarterly |
| 2023-08-02 | 10Q | KPTI/Karyopharm Therapeutics Quarterly |
| 2023-05-04 | 10Q | KPTI/Karyopharm Therapeutics Quarterly |
| 2022-11-03 | 10Q | KPTI/Karyopharm Therapeutics Quarterly |
| 2022-08-04 | 10Q | KPTI/Karyopharm Therapeutics Quarterly |
Receive KPTI News And Ratings
See the #1 stock for the next 7 days that we like better than KPTI
KPTI Financial Statistics
Sales & Book Value
| Annual Sales: | $146.03M |
|---|---|
| Cash Flow: | $-19.45M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-1.27 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -1.14000 |
|---|---|
| Net Income (TTM): | $-87.48M |
| Gross Margin: | $141.09M |
| Return on Equity: | 0% |
| Return on Assets: | -39.11% |
Karyopharm Therapeutics Earnings Forecast
Key Karyopharm Therapeutics Financial Ratios
- The Gross Profit Margin over the past 11 years for KPTI is 96.62%.
- The Selling, General & Administrative Expenses for KPTI have been equal to 90.31% of Gross Profit Margin.
- The Research & Development expenses have been 95.01% of Revenue.
- The Interest Expense is -16.65% of Operating Income.
- The Net Earning history of KPTI is -97.99% of Total Revenues.
- Per Share Earnings over the last 13 years have been positive in 6 years.
Karyopharm Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | KPTI |
| CUSIP: | 48576U |
| Website: | karyopharm.com |
Debt
| Debt-to-Equity Ratio: | -1.19 |
|---|---|
| Current Ratio: | 3 |
| Quick Ratio: | 2.69 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
KPTI Technical Analysis vs Fundamental Analysis
Sell
28
Karyopharm Therapeutics (KPTI)
is a Sell
Is Karyopharm Therapeutics a Buy or a Sell?
-
Karyopharm Therapeutics stock is rated a Sell
The current Karyopharm Therapeutics [KPTI] share price is $0.78. The Score for KPTI is 28, which is 44% below its historic median score of 50, and infers higher risk than normal.